Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Stressed-Out Cancers May Provide Drug Target

By Drug Discovery Trends Editor | December 2, 2014

Research at the University of Adelaide has discovered cancer cells may be particularly susceptible to metabolic stress – opening the way for new targeted therapy that won’t harm normal cells.
 
The researchers showed that chromosomal instability – which is a hallmark of rapidly dividing cancer cells – makes them stressed and vulnerable to mild metabolic disruption. Metabolism is the normal process by which the body turns food into energy.
 
“A common problem in treating cancers is that they don’t respond to chemotherapy, or they respond for a while, but then come back,” says lead author Dr Stephen Gregory, Senior Postdoctoral Fellow with the University’s School of Molecular and Biomedical Science.
 
“One reason this happens is because a tumour is usually not made up of identical cells but rather a diverse population of cells that changes all the time, losing and gaining chromosomes as they divide – so-called chromosomal instability. Sooner or later they change enough to be able to resist chemotherapy drugs.
 
“Our research has shown that chromosomal instability has some consequences for cells – they get stressed, and it only takes a small metabolic push to kill them.”
 
Current chemotherapy is also very toxic to all dividing cells, particularly affecting cells in hair follicles, the gut lining and blood, often causing hair loss, pain and making patients unwell.
 
“We need to find ways to target cancer cells without affecting other normal dividing cells,” says Dr Gregory.
 
The researchers induced chromosomal instability in small experimental flies, Drosophila, and found that the unstable cells were “on the edge” of how much stress they could tolerate.
 
“This is significant because a change in metabolism is something people cope with very well normally,” says Dr Gregory. “That means that we hope to be able to develop treatments that have no side effects on patients, but are able to kill off the unstable tumour cells that cause relapses.”
 
Dr Gregory says this may give some validity to theories of alternative treatments such as going on a radical diet.
 
“People who have advanced cancer which isn’t responding to chemotherapy often try a range of different treatments such as a radical diet in the hope it may help,” he says. “In some situations, it may in fact work; but we hope to be able to point the way to a more targeted approach – finding the most appropriate steps for intervention in the metabolic process that will give the best results.”
 
The research has been published in the journal Oncogene. It is funded by the National Health and Medical Research Council and continues with a recent NHMRC project grant of $593,000.
 
Source: University of Adelaide
 


Filed Under: Drug Discovery

 

Related Articles Read More >

New gonorrhea antibiotic could treat resistant infections
In door grow hemp. Cannabis at the beginning of flowering. Legal Marijuana cultivation in the home. Green background of leaves. Young cannabis plant. Medicinal indica with CBD.
Why Schedule III cannabis could be a win for Big Pharma
Red blood cells macro over red eritrosit background. Concept of blood cells count, medicine and healthcare. 3d rendering mock up
Platelet-inspired nanoparticle delivers drugs directly where they are needed
Lilly’s triple agonist delivers up to 71.2 lbs of weight loss in Phase 3 trial
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE